Compare Organon & Co. Common Stock (OGN) vs Regions Financial Corporation Common Stock (RF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Regions Financial Corporation Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Regions Financial Corporation Common Stock trades at $26.93 (market cap $23.01B). The key difference: Regions Financial Corporation Common Stock is far larger — about 6.4× Organon & Co. Common Stock's market cap, and Regions Financial Corporation Common Stock pays the higher dividend (4.05%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Regions Financial Corporation Common Stock for 6 Days on average.
| OGN | RF | |
|---|---|---|
Market Cap | $3.62B | $23.01B |
Volume | 2,892,999 | 10,095,088 |
Sector | Health | Financials |
52-Week High | $13.81 | $32.40 |
52-Week Low | $5.70 | $23.35 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.04B | $20.75B |
Dividend Yield | 0.58% | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Regions Financial (RF) trades at $27.01, down 1.32% today, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 10.98, net income margin of 29.3%, and consistent earnings beats in recent quarters. Recent news highlights dividend declarations and upcoming Q3 earnings, while the company plans significant branch expansion.
The outlook is cautiously optimistic with a $32.78 consensus price target suggesting 21% upside. Key risks include elevated expenses and weaker capital markets revenue. Analyst sentiment is mixed with 40% buy ratings, but institutional interest remains strong with Bank of America's recent $219 million investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Regions Financial Corporation Common Stock
Regions Financial is a financial holding company that operates through Regions Bank. It provides consumer, commercial, mortgage, wealth-management, and investment services across the South, Midwest, and Texas.
Read more on RF →
